Original Research Article

The outcome of implementing antimicrobial stewardship program for hospitalized children

Ahmed A. El-Nawawy1, Reham M. Wagdy1*, Ahmed Kh. Abou Ahmed1, Marwa A. Moustafa2

1Department of Paediatrics, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2Alexandria University Children’s hospital, Alexandria, Egypt

Received: 08 July 2018
Accepted: 23 July 2018

*Correspondence:
Dr. Reham M. Wagdy,
E-mail: dr_reham_wagdy@yahoo.com

ABSTRACT

Background: An effective approach to improve antimicrobial use for hospitalized patients is an antimicrobial stewardship program (ASP). The present study aimed to implement ASP for inpatient children based on prospective-audit-with-feedback intervention in order to evaluate the impact on patient’s outcome, antimicrobial use, and the hospital cost.

Methods: The study was conducted throughout 6 months over 275 children admitted with different infections at Main Children’s hospital in Alexandria included; group I (with ASP) and group II (standard antimicrobials as controls).

Results: The study revealed that on patient’s admission, single antibiotic use was higher among the ASP group while double antimicrobial therapy was higher among the non-ASP with significant difference (p=0.001). Less percentage of patients who consumed vancomycin, meropenem amoxicillin-clavulanic and metronidazole was observed among ASP group with a significant difference of the last two drugs when compared to controls (p=<0.001, 0.011, respectively). The study reported the higher percent of improved ASP patient’s after 72 hours of admission with a significant difference to controls (73.2% versus 62.5%, p=0.038). Complications occurred more likely for the non-ASP group (odds ratio 7.374 with 95% CI 1.68-32.33). In general, there was a clear reduction of the patient antibiotic cost/day and overall cost per patient, however, it was not significant among the studied patients.

Conclusions: Our local ASP model provided a high quality of care for hospitalized children and effectively reduced the antimicrobial consumption.

Keywords: Antimicrobial resistance, Antibiotic misuse, Patient’s outcome, Stewardship program

INTRODUCTION

The misuse of antimicrobial agents and the abuse of antibiotics has contributed to a growing problem of antimicrobial resistance, which has become one of the most serious and major threats to public health. In addition to increased healthcare costs, a great number of antibiotic prescriptions for children are unnecessary or inappropriate. Many children receive antibiotic prescriptions with incorrect total daily dosage or for long period of time. Moreover, the incidence of drug-related adverse events is significantly increased in instances of improper drug use which raise the risk of children morbidity and mortality. Antimicrobial stewardship program (ASP) is designed to optimize the clinical use of antimicrobial medications. It is multidisciplinary team work which promotes the appropriate use of antimicrobial through optimal selection of drug, dosage, duration and route of administration.

The current interest in ASPs for paediatric settings is reflected in many publications most of them conducted over inpatients. The American Academy of Paediatrics at 2015 highlighted the importance of ASP in paediatrics;
and recommended implementation of these programs in health care organizations that provide inpatients and outpatients care. However, development of local successful ASP program needs certain fundamentals as leadership, expert team from different fields and management guidelines. This motivated us to conduct the present study which aimed to implement ASP for hospitalized children at Alexandria University Children’s hospital and to assess the impact of ASP system on patient’s health, antimicrobial consumption and on hospital cost. The implementation of ASP and the research in this field are lacking in Egypt.

METHODS

Ethical considerations

Ethical approval was obtained from the Ethical Review Committee, Alexandria University. Ethical Review Committee of Faculty of Medicine, Alexandria University (approval no: 0103717).

Study settings and design

The current study was an interventional study conducted at Alexandria University Children's Hospital (El-Shatby) comparing the effect and value of intervention against control over a group of hospitalized children for 6 months’ duration from 2013 to 2014. El-Shatby Hospital is a tertiary care teaching hospital formed of 252 beds.

Sample size calculation

The sample size was calculated using software of Epicalc 2000 version 1.02. Based on assumption of a reduction of 25% of antibiotic use after implementing of antimicrobial stewardship program 1% alpha error and 90% power, the sample was 218 (109 in each group).

Study population

The study included all admitted cases receiving antibiotics to two units of general pediatrics wards. Patients admitted to the first unit were the intervention ASP group, while the second unit represented the control group. Each unit has specific days per week for outpatient cases admission.

Group I (Intervention-ASP)

It included all patients admitted to the first unit (31 beds) and received antimicrobials based on the implemented ASP. The ASP team consisted of pediatric assistant lecturers, residents, nursing staff, microbiologists and was supervised by two professors of pediatric department. Training was done to the health-care personnel through lectures and interactive discussions one month before implementation of the study. However, regular meetings were conducted every two weeks during the study time for assessing the feedback.

Group II (control/Non-ASP)

It included all patients admitted to the second unit (25 beds), where the routine and standard antimicrobial medications were prescribed. The team included residents, assistant lecturers, nurses and professors of paediatrics department.

Exclusion criteria from the study

Patients with hospital stay less than three days and those referred to surgery department or received antibiotics for prophylaxis as illustrated in Figure 1.

Stewardship program

The used ASP for the current study at 2014 was prospective audit with feedback intervention every two weeks. It was adopted from pediatric intensive care unit (PICU) of the same hospital which was implemented since 2007 based on the several antibiograms and medical hospital records for several years. Printed booklets including antimicrobial guidelines were available for the ASP team to be applied for the ASP group during the study time.

Questionnaire

Questionnaire was done (appendix 1) and data were collected about all patients. It included demographic data about patients and some measurable outcomes, as length of hospital stay, response to therapy weather by stewardship program or traditional method, fate of patients, developing complications during hospital stay and cost of antibiotic use and cost /patient/day. Results of both groups were compared together.

Figure 1: Flow chart of the full and the adjusted comparisons of studied groups.
Statistical analysis

The raw data were coded and transformed into coding sheets. The results were checked. Then, the data were entered into SPSS system files (SPSS package version 18). Descriptive statistics including frequency, distribution, mean, and standard deviation were used to describe different characteristics. Kolmogorov–Smirnov test was used to examine the normality of data distribution. Univariate analyses including: t-test, Mann Whitney test, was used to test the significance of results of quantitative variables. Chi-Square test, Monte Carlo test and Fisher's Exact test were used to test the significance of results of qualitative variables. The significance of the results was at the 5% level of significance.

Exclusion criteria

Hospital stay <3 days, referral to surgery and or prescribing antibiotics as prophylaxis. (ASP: Antimicrobial stewardship program.)

RESULTS

The current study included 275 children, divided into two groups, ASP group (n=113) and control group (non-ASP) (n=162) with no significant difference in the mean age of both groups (25.12±23.62 month versus 29.82±21.35 month). Respiratory infections were the predominant among the studied groups without significant difference however, cardiac diseases and septicemia were the least common but their percentage were higher among ASP groups when compared to the control group with significant difference (p<0.001, p=0.014, respectively) (Table 1).

Although the percentage of cases with positive CRP on admission was higher among the non-ASP group, the percentage of cases with very high values of CRP (>100) was higher among ASP group than controls with significant difference (p=0.008) (Table 2).

Concerning the drug prescriptions on admission, the percentage of children received single antibiotic initially was higher among the ASP group when compared to non-ASP group while the percent of children received double therapy was higher among non-ASP with significant difference to ASP (p=0.001). Less percent of cases changed antibiotics after 72 hours of initial therapy within the ASP group rather than non-ASP cases but without significant difference. The rationale of change of antimicrobial was based on either non improved cases or culture based for most of cases of ASP group. Meanwhile, higher percent of cases among non-ASP group changed antibiotics based on rational of developing complications with significant difference to study group (MC p=0.004) (Table 3).

| Item                      | ASP* group       | Non-ASP group      | Test of significance |
|---------------------------|------------------|--------------------|----------------------|
|                           | (n=113)          | (n=162)            |                      |
| Male                      | 68               | 92                 | p=0.575              |
| Female                    | 45               | 70                 |                      |
| Age (months)              | 25.12±23.62      | 29.82±21.35        | tp=0.199             |
| Weight (kg)               | 9.41±6.37        | 10.57±8.39         | tp=0.196             |
| (LOS) in (days)           | 9.29±6.49        | 8.91±8.13          | tp=0.695             |
| Urinary tract infections  | 11               | 15                 | p=0.895              |
| CNS infections            | 15               | 25                 | p=0.618              |
| Respiratory infections    | 46               | 80                 | p=0.155              |
| Gastrointestinal infections| 17              | 15                 | p=0.141              |
| Cardiac infections        | 17               | 5                  | p <0.001**           |
| Sepsis                    | 15               | 8                  | p=0.014**            |
| 6>CRP<100                 | 53               | 102                | p=0.080**            |
| CRP >100                  | 60               | 60                 |                      |
| WBC count on admission    | 13.72±8.37       | 14.33±13.06        | tp=0.663             |
| WBC shift to left         | 10               | 12                 | p=0.664              |
| WBC (no shift)            | 103              | 150                |                      |
| (WBC) toxic granules      | 13               | 22                 | p=0.611              |
| (WBC): no toxic granules  | 100              | 140                |                      |
| Sterile cultures          | 107              | 159                | FEp=0.167            |
| Positive cultures         | 6                | 3                  |                      |

tp: p value of Student t test, Pp: value of Chi- square test, MCP: p value for Monte Carlo test FEp: p value for Fisher exact test  *ASP: Antimicrobial Stewardship program**: Statistically significant at p<0.05.
Table 2: Comparison of the strategy of antibiotic prescription among studied groups.

| Item                                                   | ASP* group (n=113) | Non-ASP group (n=162) | Test of significance |
|--------------------------------------------------------|--------------------|-----------------------|----------------------|
| Number of used antimicrobials on admission             |                    |                       |                      |
| Single                                                 | 74                 | 76                    | 65.5                 | 49.9                | p=0.001**               |
| Double                                                 | 38                 | 72                    | 33.6                 | 44.4                |                       |
| More than one                                          | 1                  | 14                    | 0.9                  | 8.6                 |                       |
| The rational of choosing antimicrobial                 |                    |                       |                      |
| Physician experience                                   | 10                 | 161                   | 8.8                  | 99.4                | FeP<0.001**             |
| Documented by culture                                  | 2                  | 1                     | 1.8                  | 0.6                 |                       |
| Protocol directed                                      | 101                | 0                     | 89.4                 | 0                   |                       |
| Cases changed antibiotics after 72 hours               |                    |                       |                      |
| Yes                                                    | 24                 | 42                    | 21.2                 | 26.4                | p=0.367                |
| No**                                                   | 89                 | 117                   | 78.8                 | 73.6                |                       |
| Rationale of change of antimicrobial                   |                    |                       |                      |
| No Improvement                                         | 18                 | 21                    | 75                   | 50                  |                       |
| New culture results                                    | 4                  | 2                     | 16.7                 | 4.8                 |                       |
| Developing complications                               | 2                  | 19                    | 8.3                  | 45.2                | MCp=0.004**             |
| Use of antimicrobial combination after changing the treatment | 13                 | 14                    | 54.1                 | 33.3                | p=0.098                |
| Yes (double)                                           |                    |                       |                      |
| No (single)                                            | 11                 | 28                    | 45.8                 | 66.7                |                       |

P: p value for Chi-square test FeP: p value for Fisher Exact test MCp: p value for Monte Carlo test; *ASP: Antimicrobial Stewardship program. **Statistically significant at p<0.05; *** dropped cases.

Table 3: Comparison of the patient’s outcome of studied groups.

| Effect of drugs >72 h      | ASP group (n=113) | Non ASP group (n=162) | Odds ratio (95% CI UL-LL) |
|----------------------------|-------------------|------------------------|---------------------------|
| Improved                   | 83                | 102                    | 73.4                      | 62.9                  | p=0.038**               |
| Stationary                 | 29                | 50                     | 25.6                      | 30.8                  |                       |
| Worsle                     | 1                 | 10                     | 0.9                       | 6.1                   |                       |
| Complications***           |                    |                       |                           |                       |                       |
| Yes                        | 2                 | 19                     | 1.8                       | 11.7                  | p=0.002**               |
| No                         | 111               | 143                    | 98.2                      | 88.3                  | 7.3 (1.6-32.3)          |
| Fate                       |                    |                       |                           |                       |                       |
| Discharged cases           | 111               | 151                    | 97.3                      | 93.3                  | p=0.085                |
| Deceased cases             | 2                 | 11                     | 1.7                       | 6.7                   | 4.1 (0.89-19)          |

FeP: p value for Fisher Exact test; *ASP: Antimicrobial Stewardship program; **: Statistically significant at p<0.05; ***: pneumothorax, empyema, septic shock.

Table 3 summarized data about patient’s outcome. It showed that the percent of improved cases after 72 hours was higher in ASP group when compared to controls with significantly difference (p=0.038). The percent of complicated cases were reduced among the study group with significant difference to controls (1.8% versus 11.7%, p=0.002). Complications among non-ASP group were 7.374 times more likely than ASP group (95% CI 1.68-32.33). Discharged cases among ASP group were 4.1 times more likely than non-ASP group (95% CI 0.89-19). The number of deceased cases among study group were less than controls but without significant difference. Meanwhile, Table 4 presented the main demographic and outcome data of ASP subgroups whether deceased and discharged cases. A significant difference between both subgroups as regards the percent of cases changed antibiotics after 72 hours (*FeP=0.045) was being higher among deceased cases when compared to discharged group (100% versus 20%).

Concerning the drug consumption, the current study revealed less percentage of cases using same antimicrobials among ASP group in contrast to non-ASP cases (Table 5). The percentages of patients were on use of amoxicillin-clavulanic and metronidazole were less among ASP with significant difference when compared to non-ASP group (p≤0.001, 0.011). However, percentage of patients used ampicillin- sulbactam was higher among...
ASP groups with significant difference in (p=0.004) to controls The mean duration of the used antibiotics in days did not show statistical difference among the studied groups.

Table 4: Comparison of ASP* subgroups according to patient outcome.

| Item                                | Deceased (n=2) | Discharged (n=111) | Test of significance |
|-------------------------------------|---------------|--------------------|----------------------|
|                                     | No | % | No | % |
| Male                                | 1  | 50 | 67 | 60.4 |
| Female                              | 1  | 50 | 43 | 39.6 |
| Age (month)                         | 3.0±2.83 | 21.44±27.76       |                      |
| Weight (kg)                         | 3.75±0.35 | 9.51±6.38         |                      |
| *6 >CRP<100*                        | 0  | 58 | 52.3 |
| CRP >100                            | 2  | 100 | 53 | 47.7 |
| WBC shift to left                   | 1  | 50 | 9  | 8.1 |
| (WBC) toxic granules                | 1  | 50 | 12 | 10.8 |
| **The rational of choosing antimicrobial** |      |      |      |
| Physician experience                | 1  | 50 | 9  | 8.1 |
| Documented by culture               | 0  | 0  | 3  | 2.7 |
| Protocol directed                   | 1  | 50 | 99 | 89.2 |
| **Effect of antimicrobial therapy after 72 hours** |      |      |      |
| Improved                            | 0  | 0  | 82 | 74.5 |
| worse                               | 0  | 0  | 1  | 0.9 |
| stationary                          | 2  | 100 | 27 | 24.5 |
| Cases that changed antimicrobial after 72 hours | 2  | 100 | 22 | 20 |
| **Rationale of change of antimicrobial** |      |      |      |
| No improvement                      | 2  | 100 | 15 | 68.2 |
| New culture results                 | 0  | 0  | 4  | 18.2 |
| Developing complications            | 0  | 0  | 3  | 13.6 |
| Use of antimicrobials combination on change | 1  | 50 | 12 | 10.8 |
| Complication                        | 0  | 0  | 2  | 1.8 |

P: p value for Chi-square test FEp: p value for Fisher Exact test MCp: p value for Monte Carlo test; *ASP: Antimicrobial Stewardship program; **: Statistically significant at p<0.05.

Table 5: distribution of patients using different antibiotics, antifungal and antiviral drugs during hospitalization.

| Name of used antimicrobial          | ASP (n=113) | Non ASP (n=162) | Test of significance |
|-------------------------------------|-------------|----------------|----------------------|
|                                     | N | % | N | % |
| Cefoperazone/sulbactm               | 14 | 12.3 | 15 | 9.3 |
| Ceftriaxone                         | 57 | 50.44 | 70 | 43.2 |
| Acyclovir                           | 10 | 8.9 | 7 | 3.4 |
| Cefotaxime                          | 42 | 37.2 | 65 | 40.1 |
| Sulfame thoxazole                   | 2  | 1.8 | 1 | 0.6 |
| Amoxicillin-clavulenic              | 5  | 4.4 | 66 | 38.9 |
| Ampicillin-sulbactam                | 10 | 8.9 | 2 | 1.2 |
| Fluconazole                         | 1  | 0.9 | 5 | 3.1 |
| Metronidazole                       | 2  | 1.8 | 15 | 9.3 |
| Vancomycin                          | 29 | 25.7 | 47 | 29.9 |
| Clarithromycin                      | 1  | 0.9 | 0 | 0 |
| Meropenem                           | 13 | 11.5 | 23 | 14.2 |
| Amikacin                            | 6  | 5.3 | 3 | 1.9 |
| Azithromycin                        | 2  | 1.8 | 5 | 3.1 |
| Ceftazidime                         | 4  | 3.5 | 4 | 2.5 |
| Maxipime                            | 6  | 5.3 | - | - |

P: p value for Chi-square test FEp: p value for Fisher Exact test; *ASP: Antimicrobial Stewardship program; **: Statistically significant at p<0.05.
On the other side regarding the cost, The study showed a reduction in overall patient cost for ASP group in comparison to traditional antimicrobial group (499.20±836.46 versus 544.28±981.54) by US dollars without significant difference(P=0.657). The daily patient cost for ASP group ranged 3.75–346.23 with mean of 58.52±67.28, in comparison to range of 3.60–634.75 with for non-ASP with mean of 67.86±94.99 without significant difference (p=0.436) as shown in (Table 6).

### DISCUSSION

The need for formal ASP in paediatrics was officially recognized recently, considering the widespread use of antibiotics in children and different antimicrobial resistance patterns. In 2014, an Egyptian study Talaat et al was conducted over 18 hospitals for adults and paediatrics patients identified that about 59% of inpatients were receiving one or more antibiotic agents and that was higher than the prevalence of antibiotic use reported in similar studies in Europe 29% and most of patients were below twelve years.\(^\text{11,12}\) Egypt lack published studies about ASP for paediatric patients.

In Alexandria University Children’s hospital most of patients received antibiotics and all of them had history of receiving previous antibiotic medication prior to hospital admission. An important goal for implementing ASP is 4 Ds of Joseph and Rodvold of optimal antimicrobial therapy: right drug, right dose, de-escalation to pathogen directed therapy and right duration of therapy.\(^\text{13}\) The current study aimed to implement local ASP in paediatrics words and assessing the impact on children health status, antimicrobial use and hospital cost.

In the present study, we found respiratory tract infections were the most prevalent diagnosis among all patients with no significant difference between studied groups similarly to the study of McCulloh et al.\(^\text{14}\) Despite the spectrum of patient’s infections ranged from urinary tract infections, central nervous system, cardiac to septicemia, trivial number of the positive cultures were reported because all patients received antibiotic therapy on outpatient before hospital admission. Therefore, no relevant antimicrobial resistance study was performed.

The impact of ASP on patient outcomes is important to many practitioners but is rarely used as metrics. Most of previous studies had included mortality, length of stay (LOS) and readmission rates as parameters of patient’s outcome.\(^\text{15}\) Meanwhile, the novel parameter in the present study was early evaluation of clinical conditions whether improved or not after 72 hours of the start of medications.

The current study revealed significant improvement of ASP cases after 72 hours of admission in contrast to non-ASP cases (73.2% versus 62.5%). Also, cases that became clinically worse were statistically less in ASP group when compared to control (0.9% versus 6.2%). Moreover, the percent of cases that changed antibiotic therapy based on developing complications were significantly lower among the ASP group in comparison to the control group (8.3% versus 45.2%, p=0.004). However, changing the antibiotic depending on culture results was only 16.7% of cases in ASP group because the ASP was applied from the start “on admission”.

In spite that the study documented significant less morbidity (complications) for the intervention group, the impact of ASP on patient’s mortality showed a clinical difference (2 for ASP group versus 11 for controls) but without significance. This may be explained by small total number of patients in the study and the short duration study (4 months). Similar to the present results, two studies from Singapore General Hospital showed that ASP intervention did alter mortality rate.\(^\text{16,17}\) This was shown in a Swedish study that concluded no significant difference in mortality rates between ASP and non-ASP group with less morbidity.\(^\text{18}\) We tried to elucidate the difference inside the ASP subjected subgroups to compare discharged from deceased and it was found that the less the need to change antibiotics at 72 hours from admission, and the less use of antibiotic combination on changing the treatment after 72 hours, the less was the mortality.

Strangely enough, length of hospital stay in our study was some times longer for study group rather than the controls and this was consistent with results found by Teo et al and Mc Culloh et al.\(^\text{14,17}\) But it was contradictory to

### Table 6: Comparison between the studied groups according to cost of antimicrobial in US dollars.

| Cost                  | ASP group (n=113) | Non-ASP group (n=162) | P value |
|-----------------------|-------------------|-----------------------|---------|
| Cost/patient/day      |                   |                       |         |
| Min–Max.              | 3.75–346.23       | 3.60–634.75           |         |
| Mean±SD               | 58.52±67.28       | 67.86±94.99           | 0.436   |
| Median                | 33.70             | 36.25                 |         |
| Overall cost/patient  |                   |                       |         |
| Min–Max.              | 10.80–6016.92     | 17.0–7673.75          |         |
| Mean±SD               | 499.20±836.46     | 544.28±981.54         | 0.657   |
| Median                | 215.0             | 213.90                |         |

P value for Mann Whitney test; Test of significance <0.05.
others who reported short hospital stay under ASP protocol.  

Concerning the use of antimicrobial agents, the current study provides an insight into the potential benefit of using a prospective-audit-with-feedback strategy over other strategies to control the inappropriate antimicrobial use as they were reviewed 48-72 hours after starting therapy. The study revealed statistical significant reduction of amoxicillin-clavulanic acid and metronidazole use between the studied groups (4.4% versus 38.9% and 1.8% versus 9.3, respectively) which may explain why there was no significant difference in the length of hospital stay (LOS) (9.3 versus 8.9 days) as a direct reflection of clinical cure. Clear reduction in consumption percent of some antimicrobials was observed as vancomycin, meropenem and fluconazole even it was insignificant which matched Hersh et al who stated a decline in average antibiotic use in hospitals from 11% to 8%. The guidelines of the IDSA and SHEA revealed about 22% decrease in use of parenteral antibiotics. On the other side, Di Pentima et al reported the same but he expressed results as the number of doses per 1000 patients targeted-antimicrobial use as recommended by WHO. In the present study, the reduced consumption of drugs was explained by significant less use of antibiotic combinations on admission by ASP group because of the use of protocol of antibiotics on admission and significantly they relied on single drug prescription. The most common selected drugs were ceftriaxone, cefotaxime and vancomycin which were consistent with Newland et al. Ampicillin-sulbactam use was significantly higher among ASP group may be because of protocol directed strategy for treatment of UTI cases. As regards the cost, in general there was a decrease of about one fourth of the daily cost of antibiotic/patient (23.92%) in the ASP group and 8.29% decrease of the overall cost per patient however it was not significant as compared to non- ASP group. This may be attributed to more or less similar length of hospital stay for both studied groups. Different studies showed a reduction or savings in cost. Philemon and Agwa et al, showed reduction of antimicrobial cost per patient day by 22%- 31%. The cost-effectiveness of ASP which is the relation between reducing the price of antimicrobials and the team cost. In the present study for 2 subunits in the paediatric hospital with 275 patients admitted for 4 months the saving could be 12.375 US dollars. For a year, over 6 units it could be 111.378 US dollars. It could be a significant amount of saving in a limited resource country. Similar to an Irish study resulted in a reduction of 293.000 US dollars with a cost of 43.000 US dollars for the team yearly. Bantar study and Principe studies concluded that more saving specially in treating cases suffering from bacterial resistance.

CONCLUSION

Implementing a local ASP model with prospective-audit-with-feedback strategy is considered an inter-professional effort providing good quality of health care for hospitalized children with limiting morbidity and mortalities. It is an effective strategy for optimizing antibiotic use which reduce the antimicrobial resistance. It worth to be supported by local health authorities and recommended to be applied for all paediatric hospitals.

ACKNOWLEDGEMENTS

We gratefully acknowledge all medical and paramedical staff of El-Shathy hospital.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee, Alexandria University. Ethical Review Committee of Faculty of Medicine, Alexandria University (approval no: 0103717.)

REFERENCES

1. Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control. 2013;2:31.
2. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006;42(2):82-9.
3. Levy ER, Swami S, Dubois SG, Wendt R, Banerjee R. Rates and appropriateness of antimicrobial prescribing at an academic children's hospital, 2007-2010. Infect Control Hosp Epidemiol. 2012;33(4):346-53.
4. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance, Expert Rev Anti Infect Ther. 2008;6(5):751-63.
5. Gerding DN. The search for good antimicrobial stewardship. Jt Comm J Qual Improv. 2001;27(8):403-4.
6. Di Pentima MC, Chan S. Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital. Pediatr Infect Dis J. 2010;29(8):707-11.
7. Committee on Infectious Diseases AAoP. Kimberlin DW MTB, Jackson MA, Long SS, editor. Red Book. 30th edition. 2015.
8. Yam P, Fales D, Jemison J, Gillum M, Bernstein M. Implementation of an antimicrobial stewardship program in a rural hospital. Am J Health Syst Pharm. 2012;69(13):1142-8.
9. Masia M, Matoses C, Padilla S, Murcia A, Sanchez V, Romero I, et al. Limited efficacy of a nonrestricted intervention on antimicrobial
prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. Eur J Clin Microbiol Infect Dis. 2008;27(7):597-605.
10. Avdic E, Cushionto LA, Hughes AH, Hansen AR, Efird LE, Bartlett JG, et al. Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clin Infect Dis. 2012;54(11):1581-7.
11. Talaat M, Saied T, Kandeel A, El-Ata GA, El-Kholy A, Hafez S, et al. A Point Prevalence Survey of Antibiotic Use in 18 Hospitals in Egypt. Antibiotics (Basel). 2014;3(3):450-60.
12. Zarb P, Amadeo B, Muller A, Drapier N, Vankerckhoven V, Davey P, et al. Identification of targets for quality improvement in antimicrobial prescribing: the web-based ESAC Point Prevalence Survey 2009. J Antimicrob Chemother. 2011;66(2):443-9.
13. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother. 2008;9(4):561-75.
14. McCulloh RJ, Queen MA, Lee B, Yu D, Stach L, Goldman J, et al. Clinical Impact of an Antimicrobial Stewardship Program on Pediatric Hospitalist Practice, a 5-Year Retrospective Analysis. Hosp Pediatr. 2015;5(10):520-7.
15. Akpan MR, Ahmad R, Shebi NA, Ashiru-Oredope D. A Review of Quality Measures for Assessing the Impact of Antimicrobial Stewardship Programs in Hospitals. Antibiotics (Basel). 2016;5(1).
16. Liew YX, Lee W, Loh JC, Cai Y, Tang SS, Lim CL, et al. Impact of an antimicrobial stewardship programme on patient safety in Singapore General Hospital. Int J Antimicrob Agents. 2012;40(1):55-60.
17. Teo J, Kwa AL, Loh J, Chlebicki MP, Lee W. The effect of a whole-system approach in an antimicrobial stewardship programme at the Singapore General Hospital. Eur J Clin Microbiol Infect Dis. 2012;31(6):947-55.
18. Nilholm H, Holmstrand L, Ahl J, Mansson F, Odenholt I, Tham J, et al. An Audit-Based, Infectious Disease Specialist-Guided Antimicrobial Stewardship Program Profoundly Reduced Antibiotic Use Without Negatively Affecting Patient Outcomes. Open Forum Infect Dis. 2015;2(2):42.
19. Lee BR, Goldman JL, Yu D, Myers AL, Stach LM, Hedican E, et al. Clinical Impact of an Antibiotic Stewardship Program at a Children’s Hospital. Infect Dis Ther. 2017;6(1):103-13.
20. Hersh AL, De Lurgio SA, Thurm C, Lee BR, Weissman SJ, Courter JD, et al. Antimicrobial stewardship programs in freestanding children’s hospitals. Pediatrics. 2015;135(1):33-9.
21. Di Pentima MC, Chan S, Hossain J. Benefits of a pediatric antimicrobial stewardship program at a children’s hospital. Pediatrics. 2011;128(6):1062-70.
22. Newland JG, Stach LM, De Lurgio SA, Hedican E, Yu D, Herigon JC, et al. Impact of a Prospective-Audit-With-Feedback Antimicrobial Stewardship Program at a Children’s Hospital. J Pediatric Infect Dis Soc. 2012;1(3):179-86.
23. Philmon C, Smith T, Williamson S, Goodman E. Controlling use of antimicrobials in a community teaching hospital. Infect Control Hosp Epidemiol. 2006;27(3):239-44.
24. Agwu AL, Lee CK, Jain SK, Murray KL, Topolski J, Miller RE, et al. A World Wide Web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis. 2008;47(6):747-53.
25. Bantar C, Sartori B, Vesco E, Heft C, Saul M, Salamone F, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003;37(2):180-6.
26. Principi N, Esposito S. Antimicrobial stewardship in paediatrics. BMC Infect Dis. 2016;16(1):424.